Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Monday, Zacks.com reports.
Trillium Therapeutics has a 12-month low of C$28.50 and a 12-month high of C$39.45.
Trillium Therapeutics Company Profile
Recommended Story: Buy-Side Analysts
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.